Chronic pre-treatment with memantine prevents amyloid-beta protein-mediated long-term potentiation disruption.

Loading...
Thumbnail Image

Date

Journal Title

Journal ISSN

Volume Title

Publisher

Access

openAccess

Embargo end date

Citation

Li F, Chen X, Wang F, Xu S, Chang L, Anwyl R, Wang Q, Chronic pre-treatment with memantine prevents amyloid-beta protein-mediated long-term potentiation disruption., Neural regeneration research, 8, 1, 2013, 49-55

Abstract

Previous studies indicate that memantine, a low-affinity N-methyl-D-aspartate receptor antagonist, exerted acute protective effects against amyloid-β protein-induced neurotoxicity. In the present study, the chronic effects and mechanisms of memantine were investigated further using electrophysiological methods. The results showed that 7-day intraperitoneal application of memantine, at doses of 5 mg/kg or 20 mg/kg, did not alter hippocampal long-term potentiation induction in rats, while 40 mg/kg memantine presented potent long-term potentiation inhibition. Then further in vitro studys were carried out in 5 mg/kg and 20 mg/kg memantine treated rats. We found that 20 mg/kg memantine attenuated the potent long-term potentiation inhibition caused by exposure to amyloid-β protein in the dentate gyrus in vitro. These findings are the first to demonstrate the antagonizing effect of long-term systematic treatment of memantine against amyloid-β protein triggered long-term potentiation inhibition to improve synaptic plasticity.

Description

PUBLISHED

Endorsement

Review

Supplemented By

Referenced By

Keywords

Author's Homepage: http://people.tcd.ie/ranwyl

Author: ANWYL, ROGER

Type of material: Journal Article